Monday 19th April 2021
|Text too small?|
Cannasouth Limited’s wholly owned subsidiary Cannasouth Bioscience Limited has received approval for an additional activity under its commercial Medicinal Cannabis Licence by the Medicinal Cannabis Agency (Agency) for its facilities based in Hamilton. The new supply activity is additional to existing cultivation and possession for manufacture activities on the license.
This licence means Cannasouth is ready to distribute its imported own brand products, once registered with the Agency. Cannasouth submitted its product assessment applications for its first three products to the Agency in November 2020.
Please see the link below for details:
No comments yet
Pacific Edge Limited (NZX: PEB) Placement Upsized Following Strong Demand
24th September 2021 Morning Report
23rd September 2021 Morning Report
Pacific Edge Limited (NZX: PEB) Dual Lists on ASX; Announces Capital Raise to Accelerate
Tower Limited (NZX: TWR) Updates Guidance
South Port New Zealand Limited (NZX: SPN) 2021 Annual Report
22nd September 2021 Morning Report
Kathmandu Holdings Limited (NZX: KMD) FY21 Annual Results Announcement
Stride Property Ltd & Stride Investment Management Ltd (NZX: SPG) Update on Demerger and Office Fund
21st September 2021 Morning Report